Thymosin alpha-1: the hormone of the organ that trains your defenses

Timosina alfa-1: la hormona del órgano que entrena tus defensas

You have an organ devoted entirely to one job: teaching your immune system to tell the difference between you and everything that isn't you.

It's called the thymus. It sits behind your breastbone, just above the heart. And it works like a school: it takes in immature cells, trains them for days, graduates the ones that learned properly and discards the ones that didn't. The graduates are your T cells — the part of your defense that recognizes viruses, sick cells, and anything else that shouldn't be there.

That school runs at full capacity when you're a child. Over the years, it shrinks. It is one of the best-documented aging processes there is.

And here's the interesting part: the thymus directs that training with hormones it makes itself. One of them can be produced in a lab, has been studied for forty years, and today is an approved medicine in several countries.

It's called thymosin alpha-1. Here's what we know about it — and what we know is considerably more than usual.

The thymus: your immune system's school

This organ is worth understanding properly, because hardly anyone mentions it and it does something extraordinary.

Your bone marrow produces raw immune cells. Unformed. Those cells travel to the thymus, where they go through a demanding training that lasts a few days and involves two exams.

First exam: can this cell recognize molecules at all? If it recognizes nothing, it's useless, and it's discarded.

Second exam, the important one: does this cell attack your own body? If the answer is yes, it's eliminated on the spot. That is the mechanism that keeps your defense from turning against you.

Only a small percentage of the cells that enter the thymus graduate. The rest don't make the cut. It's a brutal filter, and that strictness is precisely what protects you.

And then the thymus shrinks

This organ reaches its peak size in childhood. From puberty onward it begins to shrink and is gradually replaced by fat. The process has its own name: thymic involution.

It isn't a disease. It happens to everyone, and it's one of the most consistent and best-described changes in human aging.

The consequence follows logically: fewer new T cells graduate as the years pass. Your defense keeps working — it carries a lifetime of accumulated memory — but it has a harder time learning to recognize things it has never seen before.

The hormone that runs that school

The thymus doesn't train by contact alone. It coordinates the process with hormones, and thymosin alpha-1 is one of the main ones.

It's small: 28 amino acids. It was isolated from the thymus in the 1970s and synthesized shortly after, which is what made serious study possible.

What it does is easiest to grasp by comparison. An antibiotic attacks the bacterium. An antiviral attacks the virus. Thymosin alpha-1 attacks nothing: it talks to your immune system.

• It pushes immature T cells to differentiate and mature — to finish their training.
• It helps the immune response become more orderly, not simply stronger. That distinction matters: a runaway immune system does damage.
• It acts as a modulator. It raises what is low and helps rein in what is disordered.

Pharmacologically it's brief: it peaks in the blood within about two hours and clears quickly. That's why it's given as subcutaneous injections spread through the week rather than as a single dose.

What sets it apart from almost every peptide

If you've read our other guides, you know our usual complaint about peptides: elegant mechanism, convinced mice, absent humans. We've written it several times, and we'll keep writing it when it applies.

Here the opposite is true, and that's worth pausing on.

And it didn't stop at trials. Thymalfasin is registered as a medicine in several countries for chronic hepatitis B and C. It went through regulatory agencies, with a dossier, with review.

That doesn't make it a miracle. It makes it something uncommon in this world: a molecule you can discuss with data instead of enthusiasm.

Where it's best demonstrated

The ground where it's been studied most is chronic hepatitis, and that makes sense: it's a disease where the problem isn't only the virus, but that the immune system never quite gets it under control.

One meta-analysis compared thymosin alpha-1 against interferon alpha — the reference treatment at the time — in patients with chronic hepatitis B.

In hepatitis B cirrhosis the evidence is more recent and points the same way. A systematic review pooled 7 randomized trials with 1,144 patients, comparing entecavir alone against entecavir plus thymosin alpha-1:

That last row is the striking one. Adding thymosin alpha-1 didn't add side effects — it reduced them. Adding something to a treatment and having people tolerate it better is not the usual outcome.

Two honest qualifications, because without them the table says more than it should. At 48 and 52 weeks the difference in viral response was no longer significant — the advantage showed up mainly early. And all the patients were from mainland China, so this needs confirming in other populations.

The most curious finding: the effect accumulates

Back to the interferon meta-analysis, because it found something that changes how you think about this treatment.

At the end of the six months of treatment, thymosin alpha-1 was not beating interferon. If the study had stopped there, the conclusion would have been that it added nothing.

But they kept measuring for six months after treatment ended. And the picture turned over:

The authors put it this way: the benefit tends to increase or accumulate gradually after therapy.

And it's consistent with what the molecule does. It doesn't kill the virus — it trains your defense. A better-trained immune system keeps working after you've stopped injecting. The effect doesn't switch off with the last dose.

It's a useful reminder for any treatment that works on your biology instead of replacing it: measuring too early can lead you to conclude it doesn't work.

The large trial that didn't go as hoped

We could leave this section out. We're not going to, because it's the part that tells you what this is actually for.

In sepsis — an infection that spirals out of control and damages organs — the immune system first overfires and then ends up exhausted. It looked like the ideal scenario for an immune modulator.

In 2013 a trial in 361 patients with severe sepsis pointed the right way: 26% mortality at 28 days with thymosin alpha-1 versus 35% in the control group. The result landed right at the edge of statistical significance. Promising, not conclusive.

So the definitive trial was run: TESTS, published in BMJ in 2025. Phase 3, double-blind, placebo-controlled, 1,106 patients across 22 centres.

The trial found no evidence that it reduces mortality in sepsis. Plainly.

What do we do with that? Three things:

• We don't hide it. It's the largest and best-conducted trial that exists on this molecule.
• We don't over-extrapolate it. Failing in intensive-care patients with organ failure says nothing about chronic hepatitis, where it did work. Different scenarios.
• We read it as a good sign about the process. That a trial like this exists is exactly what the rest of the peptide market lacks. Here, somebody bothered to actually find out.

One detail the authors flagged carefully: in subgroup analysis, patients with diabetes appeared to benefit and those under 60 appeared to do worse. These are exploratory analyses and shouldn't be treated as conclusions; they're mentioned because they guide the research that comes next.

How well it's tolerated

This is one of the better parts of the file.

Across decades of studies, what's most frequently reported is local irritation at the injection site. In the sepsis trial there were no safety differences versus placebo. In hepatitis B cirrhosis, adding it reduced adverse events.

That a molecule has been through more than a hundred clinical trials and still carries that profile says a great deal. It doesn't mean it's harmless for everyone — that's why the section below exists, and why a physician reviews it.

Where this fits into longevity

Precision matters here, because this is where the internet exaggerates most.

What is well established: the thymus shrinks with age, and production of new T cells declines. The loss of immune agility over the years is called immunosenescence, and it's real, well-documented biology.

What doesn't exist: a trial that gave thymosin alpha-1 to healthy people for years and measured whether they aged better, got sick less, or lived longer. That study is not published.

So why does it appear in a week devoted to longevity? Because the longevity worth talking about isn't living more years — it's spending more years functioning well — and a defense that responds properly is a large part of that. Thymosin alpha-1 is the molecule that works on exactly that axis, with real human evidence behind it in the conditions where it was tested.

That's a legitimate reason to have it on your radar. It is not a promise of extra years, and anyone selling it to you that way is selling smoke.

So your expectations land in the right place

None of this replaces sleeping well, moving, eating enough protein, or getting the vaccines you're due. Those have more evidence in healthy people than any peptide, and they're free or close to it.

The chronic hepatitis results were measured in people with chronic hepatitis. Nobody can promise you the same if your situation is different.

And timing matters: from what the studies show, this is thought of in months, with part of the benefit appearing even after treatment ends. If you expect to notice something in a week, the frame is wrong.

What is reasonable to expect from us: that a physician looks at your case and tells you frankly whether this makes sense for you, or whether there's a better road.

Who is this NOT for?

• If you have an active autoimmune disease. Modulating upward a system that's already attacking your own body takes medical judgment, not a web form.
• If you've had an organ transplant or take immunosuppressants. Those medications exist precisely to hold the immune response back.
• If you are pregnant, trying to conceive, or breastfeeding.
• If you have an undiagnosed acute infection — diagnosis first.
• If you're looking for something to substitute for rest, movement and real food. That doesn't exist.
• If you expect a visible result in the mirror. This doesn't work there.

Frequently asked questions

Does this "boost my immune system"?

That phrase falls short, which is why we don't use it. It isn't an accelerator: it's a modulator. It helps T cells mature and the response become more orderly. An immune system that's simply "stronger" isn't what you want — a runaway one is exactly what happens in autoimmune disease.

Is it FDA-approved?

In the United States, no — it is not approved for any use. It is registered as a medicine (thymalfasin) in several other countries for chronic hepatitis B and C. Those are two different things and worth not confusing.

Why are you telling me about the trial that failed?

Because it's the largest one there is, and because it helps you understand what this is for. A molecule that works in chronic hepatitis and doesn't rescue someone from sepsis isn't a contradiction: it's information about where it fits. If we told you only the good parts, you'd have no way to judge the rest.

How long before anything shows?

There's no established timeline outside the conditions studied. What the data do show is that the effect is measured in months, and that part of the benefit kept appearing after treatment ended. It's assessed with labs and clinical follow-up, not by how you feel.

Can I combine it with other peptides?

That's a decision for the physician reviewing your case, and it depends on what else you're using and on your history. It isn't a combination worth assembling on your own from forum posts.

What if my labs come back normal?

Then that's good news, and a serious physician will tell you instead of selling you something. Sometimes the best next step is a different one: sleep, strength training, thyroid, hormone health, or supervised weight management.

How we offer it

We wrote this article with one fixed idea: that by the time you get here you have the full picture — what was demonstrated, where it didn't work, and what's still unstudied — and can decide for yourself.

Yes, we offer thymosin alpha-1. And how we offer it matters more to us than the product.

Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. Depending on your medical history and your state, the clinician may schedule a video visit with you if they consider it necessary.

From there:

• A prescription. This is Rx. Not a supplement, not a vial from the internet.
• A licensed pharmacy. They prepare your order, with their chain of custody and their controls.
• Shipped straight to your door, in two days.
• A care team available for your questions.
• Recurring deliveries and dose adjustment with an optional monthly check-in.
• Cancel whenever you want, in one click.

And if, on reviewing your case, a different road makes more sense for you, we'll say so even when it doesn't suit us. We have clinically supervised weight management and hormone health programs, and GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149/month, by telemedicine, in Spanish and English.

Eligibility is determined by medical evaluation. Individual results vary and are not guaranteed.

See the programs →

Sources

Articles located through PubMed.

• Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. 10.1136/bmj-2024-082583
• Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013;17(1):R8. 10.1186/cc11932
• Yang YF, Zhao W, Zhong YD, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008;77(2):136-141. 10.1016/j.antiviral.2007.10.014
• Peng D, Xing HY, Li C, et al. The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):348. 10.1186/s12876-020-01477-8
• Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-885. 10.1093/ajhp/58.10.886

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medication. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform, and preparations are dispensed by licensed pharmacies. Eligibility is determined by a licensed provider. Thymosin alpha-1 is not FDA-approved for any use in the United States. Any treatment decision rests with a licensed physician evaluating your case. Individual results vary and are not guaranteed.